RxSight, Inc. RXST
At closeNov 4, 2026, 4:20 PM EST
After hours · Nov 4, 4:20 PM ET
- YTD
- -52.11%
- 1 year
- -44.56%
- Market cap
- 207.55M
- Revenue (ttm)
- 139.93M
- Profit margin
- -19.62%
- EPS (ttm)
- -1.23
- Shares out
- 40.49M
- Forward P/E
- -49.73
- YTD return
- -52.11%
- 1-year return
- -44.56%
- Volume
- 2.75M
- Avg volume
- 785.05K
- Open
- 4.11
- Previous close
- 4.59
- Day's range
- 4.11 – 5.45
- 52-week range
- 4.11 – 13.22
- Beta
- 1.22
- Analysts
- Buy
- Price target
- 41.90 (+739.7%)
- Earnings date
- Nov 7, 2024
6M -2.27 (-31.27%)
Key statistics
- Enterprise value
- 775.19M
- PEG ratio
- 0.00
- Price / sales
- 7.05
- Price / book
- 3.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 40.70%
- Free cash flow
- -9.81M
- Total cash
- 237.22M
- Total debt
- 12.30M
- Return on equity
- -12.43%
- Short % of float
- 7.35%
- 50-day average
- 29.42
- 200-day average
- 43.84
Analyst view
Consensus: buy
- Target (low)
- 28.00
- Target (mean)
- 41.90
- Target (high)
- 56.00
- Strong buy3
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 7, 2024
Expected Nov 7, 2024. Consensus EPS estimate -0.046.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2025 | Dec 1, 2024 | 0.10 | 0.03 | -0.07 | -70.00% |
| Nov 7, 2024 | Sep 1, 2024 | 0.02 | — | — | — |
| Nov 7, 2024 | Sep 1, 2024 | 0.02 | 0.00 | — | — |
| Aug 5, 2024 | Jun 1, 2024 | — | 0.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 21, 2025 | B of A Securities | main | Buy | Buy |
| Mar 19, 2025 | Stifel | main | Hold | Hold |
| Feb 26, 2025 | JP Morgan | main | Overweight | Overweight |
| Feb 26, 2025 | Stifel | main | Hold | Hold |
| Feb 26, 2025 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Feb 26, 2025 | Needham | reit | Buy | Buy |
About RxSight, Inc.
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- rxsight.com
News
Piper Sandler Maintains Neutral on RxSight, Lowers Price Target to $8 
Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $6 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Needham Maintains Buy on RxSight, Lowers Price Target to $7 
RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript 
What RxSight (RXST) Said on Its Q3 Earnings Call 
RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates 
RxSight Q3 2026 Earnings Call Transcript 
RxSight Q3 Adj. EPS $(0.21) Beats $(0.29) Estimate, Sales $24.586M Miss $27.137M Estimate 
RxSight, Inc. Reports Third Quarter 2026 Results
Your note
Sign in to keep a note on RXST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDREWS JULIE | Director | Sale | Jun 13, 2024 | 30,287 |
| CORLEY JESSE ANDERSON | Director | Purchase | Jan 15, 2025 | 0 |
| FOUNTAIN TAMARA R. | Director | Sale | Mar 11, 2025 | 24,793 |
| GOLDSHLEGER ILYA | President | Sale | Nov 28, 2024 | 43,618 |
| KURTZ RONALD M | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 8, 2024 | 828,060 |
| LINK WILLIAM J | Director | Stock Award(Grant) | Jun 5, 2024 | 48,351 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.24% | 3,743,018 | 91.22M | Dec 30, 2024 |
| Blackrock Inc. | 7.34% | 2,971,650 | 72.42M | Dec 30, 2024 |
| Vanguard Group Inc | 5.89% | 2,383,548 | 58.09M | Dec 30, 2024 |
| Bank of America Corporation | 5.33% | 2,159,923 | 52.64M | Dec 30, 2024 |
| Artisan Partners Limited Partnership | 3.83% | 1,551,620 | 37.81M | Dec 30, 2024 |
| FMR, LLC | 2.70% | 1,093,776 | 26.66M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.71% | 1,096,424 | 26.72M | Dec 30, 2024 |
| Artisan International Small-Mid Fund | 2.53% | 1,023,933 | 24.95M | Dec 30, 2024 |
| iShares Russell 2000 ETF | 2.42% | 981,420 | 23.92M | Jan 30, 2025 |
| LORD ABBETT DEVELOPING GROWTH FUND INC | 1.37% | 553,982 | 13.50M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.28% | 517,466 | 12.61M | Dec 30, 2024 |
| Invesco Discovery Fund | 1.11% | 451,119 | 10.99M | Nov 29, 2024 |